/PRNewswire/ -- Regulated information – Inside information – UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered...

Related Keywords

Japan , California , United States , Emeryville , Brussels , Bruxelles Capitale , Belgium , Dravetc Dravet , Charl Van Zyl , Tevard Biosciences , Stephenj Farr , Twitter , Zogenix Inc , Barclays , Zinc Merger Sub Inc , Committee For Medicinal Products Human Use , National Institute Of Neurological Disorders , Neurology Head Of Europe International , Statement Of Zogenix Inc , Drug Administration , Latham Watkins , Lazard , Covington Burling , Exchange Commission , Zogenix Press , European Medicines Agency , Euronext , New Drug Application , Priority Review , Executive Vice President , International Markets , Chief Executive Officer , Zinc Merger Sub , Capital Markets Call , Prescribing Information , Boxed Warning , Euronext Brussels , Information About , Recommendation Statement , Information Agent , Looking Statement , Private Securities Litigation Reform Act , New Therapy , Medicinal Products , Human Use , Zogenix Submits New Drug Application , Epileptic Seizures Associated , Zogenix Pipeline , Zogenix Submits Type , Seizures Associated , Supplemental New Drug Application , Lennox Gastaut Syndrome , Core Dravet Syndrome , Med Child , Dravet Syndrome , National Institute , Neurological Disorders , Lennox Gastaut Syndrome Information , Last Accessed Jan , Fintepla Summary , Ucb And Zogenix ,